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Summary
We engineered a novel ligand-regulated peptide
(LiRP) system where the binding activity of intracellu-
lar peptides is controlled by a cell-permeable small
molecule. In the absence of ligand, peptides ex-
pressed as fusions in an FKBP-peptide-FRB-GST
LiRP scaffold protein are free to interact with target
proteins. In the presence of the ligand rapamycin, or
the nonimmunosuppressive rapamycin derivative
AP23102, the scaffold protein undergoes a conforma-
tional change that prevents the interaction of the pep-
tide with the target protein. The modular design of the
scaffold enables the creation of LiRPs through ratio-
nal design or selection from combinatorial peptide li-
braries. Using these methods, we identified LiRPs
that interact with three independent targets: retino-
blastoma protein, c-Src, and the AMP-activated pro-
tein kinase. The LiRP system should provide a gen-
eral method to temporally and spatially regulate
protein function in cells and organisms.
Introduction
With the sequence of the human genome complete, a
major challenge of life science research is the determi-
nation of the cellular functions of the predicted pro-
teins. Indeed, this challenge is further complicated be-
cause many genes encode multiple protein domains
with distinct functions and/or multiple mRNA splice
variants. Biologists and chemists have developed a
broad set of experimental tools to elucidate the func-
tions of proteins and other macromolecules in cells and
organisms. These approaches offer distinct advan-
tages/disadvantages and can be differentiated by their
scope of application, specificity, timescale of regula-
tion, dose dependence, and reversibility.
Genetic approaches are the most common methods
to identify the functions of proteins. Genetic mutation
targets a single allele and provides absolute specificity.
However, there are disadvantages to this approach:
limitation to organisms that are tractable to genetic
protocols; difficulty in achieving temporal control of in-
hibition; potential compensation by functionally related
proteins; difficulty in identifying mutations that inhibit
protein subdomains when little is known about the
structure/function of a target; and embryonic lethality
when gene function is studied in whole organisms [1,*Correspondence: belshaw@chem.wisc.edu
3 These authors contributed equally to this work.2]. An additional genetic approach that has gained
widespread use is RNA interference (RNAi) [3]. RNAi al-
lows for specific inhibition of a target protein from
knowledge of its gene sequence alone. However, the
functions of protein subdomains cannot be directly in-
vestigated. In addition, temporal control of target inhi-
bition depends on the timescale of mRNA and protein
degradation and typically ranges between hours and
days.
The chemical modulation of protein function with
small molecules has a long history in the discipline of
pharmacology. More recently, the field of chemical ge-
netics [4] has sought to systematically identify modula-
tors of target protein function by screening libraries of
small molecules. Particular advantages of the small-
molecule approach are precise temporal control of tar-
get function (onset of small-molecule action ranges
from seconds to minutes), control of the level of modu-
lation by varying the dose, reversibility of modulation
by removal of the compound, and ease of use in a vari-
ety of experimental systems. The small-molecule ap-
proach has limitations in specificity and scope, be-
cause families of related proteins are often influenced,
and many targets such as protein-protein interactions
are not readily regulated by small molecules.
An additional approach to study protein function in-
volves the use of genetically encoded macromolecules
[5–7]. Nucleic acids or polypeptides that bind targets
with high affinity and specificity can be selected from
combinatorial libraries. These “aptamers” can be ex-
pressed and used to modulate the function of their tar-
gets inside cells. Indeed, peptide aptamers expressed
as fusions to stable globular proteins have had wide-
spread use in this regard. Additionally, peptide apta-
mers can be directed to virtually any compartment
within a cell using the appropriate trafficking signals.
The aptamer approach allows the activity of individual
protein domains to be studied when little is known
about their structure/function. However, a disadvan-
tage of the aptamer approach is that it lacks the exqui-
site temporal control provided by small molecules.
An emerging theme for solutions to these problems
is to combine the advantages of small molecules and
genetically encoded macromolecules. A number of dif-
ferent combined chemical and genetic approaches
have already been published: the regulated association
of engineered proteins with chemical inducers of di-
merization [8, 9]; the design of noncovalent [10–15] and
covalent [16–18] ligands specific for engineered or mu-
tant [19, 20] proteins; systems for ligand-regulated ex-
pression [21–28], ligand-regulated deaggregation [29],
ligand-regulated RNA aptamers [30], riboswitches [31,
32], and allosteric ribozymes [32, 33]; and ligand-
induced covalent complex formation [34]. These ap-
proaches provide the additional advantage that the ac-
tivity of the small molecule is restricted to the subset
of cells or tissues expressing the genetically encoded
effectors.
Here, we report the design of a novel ligand-regulated
peptide (LiRP) system for the regulation of peptide/target
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848protein interactions. A tripartite scaffold protein enables g
rthe cell-permeable small molecule rapamycin to regulate
the binding interactions of peptides with target proteins. t
IThe overall scaffold protein contains three protein do-
mains: FK506 binding protein 12 (FKBP) [35, 36]; FKBP- d
mrapamycin binding domain [37] (FRB) from the target of
rapamycin protein [35, 36, 38, 39] (FRAP, mTOR, RAFT); p
and glutathione S-transferase (GST) (Figure 1). Peptides h
presented in the context of the FKBP-peptide-FRB- s
GST scaffold protein are free to interact with target pro- t
teins in the absence of rapamycin. In the presence of s
rapamycin, a complex forms between FKBP, rapa- t
mycin, and FRB [39]. This complex limits the conforma- G
tional freedom of the peptide, preventing interactions E
with the target protein. In addition, the larger GST pro- T
tein domain acts to sterically occlude access of the a
peptide to the target protein. The LiRP system should a
provide a unique tool for studying dynamic intracellular A
processes by controlling the binding activity of peptide s
regulators of target protein function. As a result, it rep- L
resents a novel addition to a set of approaches that
combine the benefits of small molecules with the bene-
Rfits of macromolecular recognition. Moreover, the LiRP
Rsystem should provide unique advantages over these
Wsystems for the study of protein function.
i
sResults
t
sRational Design of the LiRP Scaffold Protein
fWe based our scaffold protein on the trimeric interac-Figure 1. LiRP Identification and Rapamycin-
Induced Conformational Change
(A) Schematic representation of the YTH sys-
tem used to identify LiRPs. Target proteins
(“baits”) are expressed as fusions to the Gal4
DNA binding domain (DB; yellow). The LiRP
scaffold presenting various targeting pep-
tides (“preys”) are expressed as fusions to
the Gal4 activation domain (AD; white). Bait
and prey interaction promotes transcription
of GAL1-HIS3 and GAL2-ADE2 reporter
genes that promote cell growth on media
lacking histidine and adenine, respectively.
Rapamycin promotes a conformational
change in the LiRP scaffold that prevents in-
teraction of prey peptides with bait proteins
and transcription of reporter genes. FKBP
(blue); FRB (green); GST (orange); RAP, rapa-
mycin (black).
(B) Molecular model of the LiRP system. Di-
vergent stereo pair showing FKBP (blue sur-
face), FRB (green surface), GST (orange sur-
face), ELLYCYEGS peptide (sticks, colored
by element with surface), and rapamycin
(sticks, colored by element). This model was
created and energy minimized using Sybyl
molecular modeling software (Tripos corpo-
ration), and the image was rendered in Py-
MOL (W.L. DeLano, “The PyMOL Molecular
Graphics System” [2002]; http://www.pymol.
org).tion of FKBP, rapamycin, and the FRB domain [39]. Byenerating an FKBP-peptide-FRB fusion protein, we
easoned that binding rapamycin would cause a reduc-
ion in the conformational freedom of the peptide linker.
n addition, we observed that the C terminus of the FRB
omain was in close proximity to the peptide linker and
ight be fused to the large GST protein domain to
hysically occlude access to the peptide (Figure 1). We
ypothesized that conformational constraint and/or
teric occlusion would prevent interaction of the pep-
ide linker with the target protein. Overall, the LiRP
caffold has the following primary sequence: HA epi-
ope tag-hFKBP12 (amino acids 2–108)-EL-peptide-
S-hFRB (amino acids 2021–2112 of mTOR, T2098L)-
F-GST (amino acids 2–218 of S. japonicum GST). The
2098L mutation was included in the FRB domain to
llow conformational switching with both rapamycin
nd nonimmunosuppressive derivatives such as
P23102 [40]. We utilized the yeast two-hybrid (YTH)
ystem to screen rationally designed LiRPs or to select
iRPs from a combinatorial peptide library (Figure 1A).
ational Design of a LiRP Targeting
etinoblastoma Protein
e chose human retinoblastoma protein (hRb) as an
nitial target for the LiRP system. hRb has a highly con-
erved surface cleft that binds to peptides that contain
he sequence LXCXE [41]. A YTH bait plasmid was con-
tructed that encodes a Gal4 DNA binding domain (DB)
usion to hRb (DB-hRb). DNA encoding LYCYE-contain-ing peptides of varying length from the HPV16 E7 onco-
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(A) Primary sequence for each of the three E7 peptides displayed
by the FKBP-peptide-FRB-GST scaffold protein (Scaff-peptide).
(B) YTH results. Yeast strains were replica plated onto experimental
plates: SC-Leu-Trp, SC-Leu-Trp-Adenine, SC-Leu-Trp-Adenine + 1
M rapamycin, and SC-Leu-Trp-Adenine + 1 M FK520. Each
strain is numbered and expresses the following pairs of fusion pro-
teins: strain 1, DB-FKBP/full-length Gal4 transcription factor; strain
2, DB-hRb/Scaff-LYCYE; strain 3, DB-hRb/Scaff-DLYCYEQ; strain
4, DB-hRb/Scaff-DLYCYEQLN; strain 5, DB-hRb/Scaff (No GST)-LY-
CYE; strain 6, DB-hRb/Scaff-SS; strain 7, empty bait vector/Scaff-
LYCYE; strain 8, empty bait vector/Scaff-DLYCYEQ; strain 9, empty
bait vector/Scaff-DLYCYEQLN; strain 10, DB-FKBP/AD-FRB; strain
11, DB-calcineurin A/AD-FKBP.
(C) LiRP steady-state expression levels. (Upper panel) Anti-HA
Western blot for strain 2 grown in the presence or absence of 1 M
rapamycin. (Middle panel) Anti-HA Western blot for strains grown
in the absence of rapamycin. Strain 10 lacks the expression of an
HA-tagged fusion protein and serves as a negative control. (Lower
panel) Coomassie-stained gel for strains grown in the absence of
rapamycin. Equivalent amounts of total protein per lane as for iden-
tical samples run in the middle panel.protein (Figure 2A) was cloned into a YTH prey plasmid
that encodes a Gal4 activation domain (AD) fusion to
the LiRP scaffold protein (AD-HA-FKBP-E7 peptide-
FRB-GST). Bait and prey plasmids were cotransformed
into YTH strain PJ69-4A (tor2-1 Dfpr1), and strains ex-
pressing both bait and prey fusion proteins were se-
lected on SC-Leu-Trp media. These strains were replicaplated onto SC-Leu-Trp-Adenine ± 1 M rapamycin
plates to assay for rapamycin-regulated activation of
the GAL2-ADE2 reporter gene. In addition, an SC-Leu-
Trp-Adenine plate containing 1 M of the small mole-
cule FK520 was used as a negative control. Like rapa-
mycin, FK520 binds with high affinity to FKBP [42].
However, unlike rapamycin, this complex binds to
calcineurin and not to FRB [43]. E7 peptides of all three
lengths interacted with the hRb bait when presented
from the LiRP scaffold (Figure 2B; strains 2, 3, and 4).
In each case, expression of DB-hRb was required for
reporter gene activation (Figure 2B; strains 7, 8, and 9).
The LiRP scaffold itself did not interact with DB-hRb
(Figure 2B; strain 6). Interestingly, the LYCYE peptide
alone showed a rapamycin-dependent growth inhibi-
tion (Figure 2B; strain 2). In contrast, the LiRP scaffold
presenting LYCYE-containing peptides only 2 and 4
amino acids greater in length did not display rapa-
mycin-dependent growth inhibition (Figure 2B; strains
3 and 4). An identical scaffold protein displaying the
LYCYE peptide but lacking the GST moiety (AD-HA-
FKBP-LYCYE-FRB) did not show rapamycin-dependent
growth inhibition (Figure 2B; strain 5). Therefore, for the
LYCYE sequence, the potential conformational con-
straint provided by FKBP-rapamycin-FRB complex
formation alone appears insufficient, and the steric oc-
clusion provided by GST is required for the rapamycin-
dependent phenotype. When FK520 was substituted
for rapamycin, ligand-dependent growth inhibition was
not observed for the LiRP scaffold presenting the LY-
CYE peptide (Figure 2B; strain 2). Strains expressing
either DB-calcineurin A/AD-FKBP or DB-FKBP/AD-
FRB, included as positive controls for ligand function,
displayed anticipated phenotypes: reporter genes were
activated in these strains upon formation of calcineurin
A-FK520-FKBP or FKBP-rapamycin-FRB complexes,
respectively (Figure 2B; strains 10 and 11). Importantly,
an anti-HA Western blot using cells grown in the pres-
ence or absence of rapamycin showed no significant
change in expression levels of the LiRP scaffold dis-
playing the LYCYE peptide (Figure 2C, upper panel).
This result shows that the mechanism of rapamycin
regulation is not due to a rapamycin-induced decrease
in the expression level of the LiRP scaffold. In addition,
approximately equal amounts of fusion protein are de-
tected for each of the strains expressing E7 peptides
displayed from the LiRP scaffold (Figure 2C, lower
panel) showing that the rapamycin-regulated pheno-
type for E7 peptides of varying length is not the result
of differences in expression levels.
Rational Design of LiRPs Targeting c-Src SH3
We chose the mouse c-Src SH3 domain as a second
target protein. The SH3 domain of c-Src binds to two
classes of polyproline type II helices in opposite orien-
tations: class I peptides with a consensus sequence
of RXLPPLP and class II peptides with a consensus
sequence of XPPLPXR [44]. A YTH bait plasmid was
constructed that encodes the protein DB-c-Src that in-
cludes both SH3 and SH2 domains. This fusion protein
was shown to interact with a known c-Src SH3 binding
protein fused to AD, AD-p130Cas (Figure 3B; strain 11)
[45]. DNA encoding the peptides RALPPLP (class I pep-
tide) and PPLPPR (class II peptide) was cloned into a
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(A) Primary sequence for class I and class II peptides displayed by
the FKBP-peptide-FRB-GST scaffold protein (Scaff-peptide). I
(B) YTH results. Yeast strains were replica plated onto experimental P
plates: SC-Leu-Trp, SC-Leu-Trp-Adenine, SC-Leu-Trp-Adenine +
W1M rapamycin, and SC-Leu-Trp-Adenine + 1 M FK520. Each
kstrain is numbered and expresses the following pairs of fusion pro-
teins: strain 1, DB-FKBP/full-length Gal4 transcription factor; strain L
2, DB-SrcN/Scaff (No GST)-RALPPLP; strain 3, DB-SrcN/Scaff (No p
GST)-PPLPPR; strain 4, DB-SrcN/Scaff-RALPPLP; strain 5, DB- A
SrcN/Scaff-PPLPPR; strain 6, DB-SrcN/Scaff; strain 7, empty bait s
vector/Scaff-PPLPPR; strain 8, empty bait vector/Scaff-RALPPLP;
rstrain 9, DB-CnA/AD-FKBP; strain 10, DB-FKBP/AD-FRB; strain 11,
sDB-SrcN/AD-Cas.
(C) Anti-HA Western blots. Strains 4, 5, and 6 grown in the presence c
or absence of 1 M rapamycin. G
m
F
fYTH prey plasmid that encodes an AD fusion to the
LiRP scaffold (AD-HA-FKBP-class I/II peptide-FRB- w
sGST) (Figure 3A). Bait and prey plasmids were cotrans-
formed into YTH strain PJ69-4A (tor2-1 Dfpr1), and w
tstrains expressing both bait and prey fusion proteins
were selected on SC-Leu-Trp media. Strains were rep- b
flica plated onto SC-Leu-Trp-Adenine ± 1 M rapamycin
plates to assay for rapamycin-regulated activation of T
mthe GAL2-ADE2 reporter gene or ±1 M FK520 as a
negative control. Both the class I and class II peptides i
tinteracted with the c-Src SH3 domain when presented
from the LiRP scaffold (Figure 3B; strains 4 and 5). In
ieach case, expression of DB-c-Src was required for re-
porter gene activation (Figure 3B; strains 7 and 8). The 1
tLiRP scaffold itself did not interact with DB-c-Src (Fig-
ure 3B; strain 6). In the presence of rapamycin, both t
cclass I and class II peptides presented from the LiRP
scaffold showed rapamycin-dependent growth inhibi- t
ltion (Figure 3B; strains 4 and 5). An identical scaffoldrotein displaying the class I and class II peptides but
acking GST (AD-HA-FKBP-class I/II peptide-FRB) did
ot show rapamycin-dependent growth inhibition (Fig-
re 3B; strains 2 and 3), demonstrating again that the
teric bulk of GST is necessary for the rapamycin-
ependent growth inhibition. Ligand-dependent growth
nhibition was not observed for the LiRP scaffold pre-
enting class I/II peptides when FK520 was substituted
or rapamycin (Figure 3B; strains 4 and 5). Importantly,
nti-HA Western blots for strains grown in the presence
r absence of rapamycin display no significant change
n expression levels for class I and class II peptides
resented from the LiRP scaffold (Figure 3C). This re-
ult shows that the mechanism of rapamycin regulation
s not due to a ligand-induced decrease in expression
evel of the LiRP scaffolds.
ose-Response Experiments with Rationally
esigned LiRPs
e further characterized ligand-mediated growth inhi-
ition in the YTH system by varying the amount of ra-
amycin or the nonimmunosuppressive rapamycin
erivative AP23102 (Ariad Pharmaceuticals) in Sc-Leu-
rp-Adenine liquid culture (Figure 4). In all cases, growth
nhibition increased with increasing concentrations of
igand. As expected, no growth inhibition was detected
n the presence of rapamycin or AP23102 for a control
train expressing DB-c-Src/AD-p130Cas fusion pro-
eins.
dentification of LiRPs from a Combinatorial
eptide Library
e chose hRb and the mouse AMP-activated protein
inase α1 subunit (AMPK-α1) as targets for selection of
iRPs from a randomized peptide library. A YTH bait
lasmid was constructed that encodes a DB fusion to
MPK-α1 (DB-AMPK α1). A plasmid DNA library was
ynthesized that encodes seven random amino acid
esidues linking the FKBP and FRB domains of the LiRP
caffold. The plasmid DNA library was constructed by
loning 5#-GAGCTC (SacI site)-(NNS; N = A, G, T, C, S =
, C)7-GGATCC (BamHI site)-3# dsDNA library frag-
ents into vector pPrey-Scaffold encoding the AD-HA-
KBP-EL(SacI site)-peptide-GS(BamHI site)-FRB-GST
usion protein. The plasmid DNA library consisted of
7.5 × 107 independent members, where w52% pos-
essed library inserts of unit length. The remaining
48% of library members either had inserts greater
han unit length (resulting from ligation of multiple li-
rary inserts), had no insert, or possessed cloning arti-
acts that removed portions of FKBP, FRB, and/or GST.
able 1 and Table 2 list the insert sequences and rapa-
ycin-regulated phenotypes for library members that
nteract with hRb and AMPK-α1 bait proteins, respec-
ively.
In selections targeting hRb, seven colonies were
dentified from a total of 1.02 × 106 transformants. Table
lists the sequences of seven unique clones confirmed
o have a positive YTH interaction after retransforma-
ion into YTH strain PJ69-4A (tor2-1 Dfpr1). All seven
lones contained the LXCXE sequence motif. Five of
he seven clones were identified as rapamycin-regu-
ated LiRPs. For all seven clones, the register of the
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mycin and AP23102
YTH strains were grown in SC-Leu-Trp-Ade-
nine liquid culture in the presence of 0, 250
nM, 500 nM, or 1 M rapamycin or the nonim-
munosuppressive rapamycin analog AP23102.
Turbidity (OD600) was measured at a represen-
tative time point as the no compound cultures
approached saturation (OD600= 6–10). The
known interaction pair p130Cas/c-Src is in-
cluded to show that rapamycin has little effect
at the concentrations tested.AMPK-α1 by rational design or selection from a random
Table 1. LiRPs Targeting hRb Selected from the AD-HA-FKBP-
(X)7-FRB-GST Combinatorial Peptide Library
Clone ID Sequence LiRP Activity
Rb-1-1 LRCTEEV +
Rb-1-2 LYCWEEL −
Rb-1-3 NLYCTEN −
Rb-2-1 LFCDEARGSCIGLTYS +
Rb-2-2 LECEEAI +
Rb-2-3 LMCMEED +
Rb-2-4 SLLCREK +
The LXCXE motif is present in all clones (underlined). LiRP activity
was determined by replica plating strains onto SC-Leu-Trp-
Adenine ± 1 M rapamycin plates. +, robust growth in the absence
of rapamycin with no detectable growth in the presence of
rapamycin; −, robust growth in the presence or absence of
rapamycin. Clone Rb-2-1 is the result of aberrant ligation of two
DNA library inserts into the same plasmid DNA vector.LXCXE motif begins at either the first or second ran-
domized amino acid residue. Both LiRP and non-LiRP
clones are represented in both registers. For example,
the sequences LRCTEEV and SLLCREK were rapa-
mycin regulated, whereas the sequences LYCWEEL
and NLYCTEN interacted with DB-hRb in the presence
and absence of rapamycin. These results demonstrate
that the regulation of peptide-target protein interactions
with rapamycin can be sensitive to subtle changes in
peptide sequence, possibly due to sequence-dependent
peptide conformations in the rapamycin bound LiRP
scaffold.
In selections targeting AMPK-α1, forty interacting
colonies were identified from 1.23 × 106 transformants.
Table 2 lists the sequences of fifteen unique clones that
were confirmed for a positive YTH interaction following
retransformation into YTH strain PJ69-4A (tor2-1
Dfpr1). All fifteen clones showed rapamycin-regulated
interaction with AMPK-α1. Each clone encoded a sim-
ilar peptide sequence with the consensus motif (K/R)
R(Q/M)RXXX.
Discussion
We have identified LiRPs that target hRb, c-Src, andpeptide library. Our results suggest that LiRPs can be
identified for a wide variety of target proteins. In cases
where peptide sequences are known to interact with
target proteins, these sequences or sequence variants
can be tested for functionality in the LiRP system. Alter-
natively, if peptides are unknown or nonfunctional, it is
possible to identify LiRPs from random peptide librar-
ies. For example, a LiRP with the sequence SLLCREK
was identified from a screen of a random peptide library
after previous efforts suggested that peptides similar to
DLYCYEQ would lack rapamycin regulation (Figure 2).
In addition, a screen of a random peptide library for
LiRPs that target AMPK-α1 identified 15 rapamycin-
regulated clones with the consensus sequence (K/R)R
(Q/M)RXXX. To our knowledge, this sequence motif does
not match peptide sequences known to bind AMPK,
and we are currently investigating its biological rele-
vance. Together, these results demonstrate that novel
LiRPs can be identified by screening random peptide
libraries. Moreover, this approach may prove success-
ful when known peptides for target proteins are unavail-
able or rational design efforts have previously failed.Table 2. LiRPs Targeting AMPK-α1 Selected from the AD-HA-
FKBP-(X)7-FRB-GST Combinatorial Peptide Library
Clone ID Sequence LiRP Activity
α1-1 YRQRDKF +
α1-2 RRQRFMFGSCIGLTYS +
α1-3 RRMWPWS +
α1-4 RRMRPCR +
α1-5 RRQCRHL +
α1-6 RRQSHWS +
α1-7 KRMRTWK +
α1-8 KRQRWCY +
α1-9 KRQRDFT +
α1-10 KRQTLWW +
α1-11 RRCRERT +
α1-12 QRMRDRS +
α1-13 RHQSWWH +
α1-14 KRMRSSV +
α1-15 RMMRSRT +
LiRP activity was determined by replica plating strains onto SC-
Leu-Trp-Adenine ± 1 M rapamycin plates. +, robust growth in the
absence of rapamycin with no detectable growth in the presence
of rapamycin; −, robust growth in the presence or absence of
rapamycin. Clone α1-2 is the result of aberrant ligation of two DNA
library inserts into the same plasmid DNA vector.
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bcombination for the LiRP system will likely depend on
the structural characteristics of the interaction. For the t
Trationally designed LiRPs presented here, the peptides
bind to shallow pockets on the surface of the target r
aprotein in extended conformations: the LYCYE motif
adopts a β-strand-like structure; and the c-Src SH3 p
tpeptides adopt polyproline helices [41, 44]. These pep-
tide-target protein interactions represent challenging c
examples for regulation through conformational con-
straint alone. However, the combination of conforma- c
ptional constraint and steric occlusion was able to im-
part rapamycin regulation to these peptides. Short t
ppeptides of five to seven amino acid residues are likely
sufficient to bind to the shallow clefts typical of enzyme s
ractive sites. The isolation of LiRPs Rb-2-1 and α1-2 (Ta-
bles 1 and 2), each containing an irregular peptide in- p
psert 16 amino acids in length, suggests that the LiRP
scaffold has the potential to regulate longer peptides. a
rOngoing investigations using peptide libraries greater
than seven amino acid residues will identify if longer s
epeptides can be regulated as LiRPs. In addition, we are
investigating the use of other steric occlusion domains d
oand domain-domain fusion junctions to potentially gen-
eralize the LiRP scaffold to longer peptides. If longer p
apeptides can be used, they may provide enhanced af-
finity/specificity for interaction with target proteins. i
IOur data support a mechanism of rapamycin-induced
conformational change of the LiRP scaffold protein and b
psteric occlusion mediated by GST (Figure 1). In all
cases tested, GST was a required component of the m
3scaffold, indicating the importance of steric occlusion
for regulating these peptide-protein interactions. The g
csteady-state expression levels of rationally designed
sLiRPs did not detectably change in the presence or ab-
tsence of rapamycin (Figures 2C and 3C), indicating that
ga rapamycin-induced decrease in expression levels is
cnot the mechanism of rapamycin-mediated growth inhi-
ebition. Moreover, introduction of the S2035T mutation
Linto FRB, which blocks interaction of FKBP-rapamycin
mand FRB [37], abolishes LiRP activity when introduced
ginto the LYCYE-LiRP (data not shown). Figure 1B il-
tlustrates a model of the LiRP scaffold showing a single
tmolecule of GST. However, GST is a dimeric enzyme
t[46], and the dimer interface of GST in the LiRP scaffold
fis solvent exposed. Therefore, the potential exists for
pheterodimerization of the LiRP scaffold with endoge-
anous GST or homodimerization between two scaffold
nmolecules. In either case, molecular modeling suggests
cthat dimerization would only slightly increase the steric
ebulk in the vicinity of the peptide. The functional conse-
tquence of these potential dimerization events is cur-
arently unknown.
LThe LiRP system should be useful for investigations
tof target protein function in mammalian cells. Peptides
mpresented from the LiRP scaffold can be expressed inside
pcells and are free to interact with target proteins. Addition
hof rapamycin promotes a rapid, dose-dependent, and po-
atentially reversible decrease in the LiRP-target protein in-
teraction. However, the immunosuppressive properties of
Srapamycin may potentially complicate the interpretation
of experimental results in experimental applications. For-
tunately, nonimmunosuppressive rapamycin analogs have N
tbeen developed that possess good pharmacologicalroperties, are physiologically inert, and can induce
inding interactions between FKBP and a T2098L mu-
ant of FRB [47, 48]. The LiRP scaffold incorporates the
2098L FRB mutation, and we demonstrated ligand
egulation with the nonimmunosuppressive rapamycin
nalog AP23102 (Figure 4). Nonimmunosuppressive ra-
amycin analogs should allow the use of the LiRP sys-
em in cells and whole organisms without the compli-
ating effects of mTOR inhibition.
The LiRP system provides potential advantages
ompared to similar approaches for regulating target
rotein function. The LiRP system is functionally similar
o the ligand-regulated RNA aptamer (LiRA) approach
ublished by Vuyisich and Beal [30]. The LiRP and LiRA
ystems allow expression of transgenes encoding mac-
omolecules that can potentially interact with target
roteins with high affinity/specificity, and both offer the
otential rapid relief of target protein interaction upon
ddition of a small-molecule ligand (switch-off of mac-
omolecule binding). Both systems offer advantages
imilar to peptide and RNA aptamers [5–7]: transgene
xpression precludes the need for mutagenesis of en-
ogenous transcription cassettes, a requirement of
ther approaches [8–29, 31–34]; the activity of target
rotein subdomains can be regulated while leaving the
ctivity of other subdomains intact, which is difficult or
mpossible to achieve with other approaches [3, 31–33].
n addition, the use of small molecules to regulate the
inding activity of macromolecules should allow tem-
oral control of target protein activity on timescales
arkedly faster than related approaches [21–29, 31, 33,
4]. Thus, both systems offer the potential to investi-
ate target protein function in dynamic cellular pro-
esses (e.g., signal transduction, etc.). The overall
cope of both the LiRP and LiRA systems could be ex-
ended by variants where macromolecules are trig-
ered to bind to target proteins by the addition of a
ell-permeable small molecule (switch-on of macromol-
cule binding). Indeed, it may be possible to switch on
iRP-target protein interactions by displacing rapa-
ycin from the closed complex with high-affinity li-
ands that bind FKBP and induce the open conforma-
ion of the scaffold. As compared with the LiRA system,
he LiRP system offers a number of unique advantages:
he ability to rationally design LiRPs without the need
or selection from combinatorial libraries using known
eptide ligands for target proteins; optimized YTH re-
gents for the facile selection of LiRPs from combi-
atorial libraries; the availability of physiologically inert,
ell-permeable ligands; potentially higher steady-state
xpression levels of LiRP fusion proteins compared
o RNA aptamers [6, 32], an important parameter for
chieving potent target inhibition; the potential to direct
iRP activity to subcellular compartments with protein
rafficking signals; and the functionality of peptides for
odulating protein/protein interactions. As these ap-
roaches are further developed, it is likely that each will
ave particular advantages and find complementary
pplications in biological investigations.
ignificance
ew experimental approaches for regulating the ac-
ivity of proteins will allow novel insight into their cel-
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853lular functions. We have developed the ligand-regu-
lated peptide (LiRP) system as a general approach for
the control of intracellular peptide binding activity by
the addition of a cell-permeable small molecule.
LiRPs will likely combine the advantages of peptides
(broad target applicability and binding specificity)
and small molecules (rapid onset of action, dose de-
pendence, and reversibility) for the study of target
protein function. As a result, LiRPs will likely enable
new experimental approaches for the investigation of
dynamic cellular processes. In addition, the LiRP sys-
tem provides unique advantages compared with sim-
ilar approaches, including the ability to rationally de-
sign LiRPs using known peptide sequences and the
use of physiologically inert, cell-permeable ligands.
In summary, the rational design or selection of LiRPs
from random peptide libraries should allow the tem-
poral (timing of ligand addition) and spatial (tissue
and cell compartment restriction) control of a broad
range of macromolecule interactions.
Experimental Procedures
Isolation of Rapamycin and FK520
Rapamycin-producing strain Streptomyces hygroscopicus subsp.
hygroscopicus (ATCC #29253) and FK520-producing strain Strep-
tomyces hygroscopicus subsp. ascomyceticus (ATCC #55087)
spores were produced on ISP2 agar media in petri dishes at 30°C
for 14 days. Glycerol (20%) was added to the petri dishes to pre-
pare a spore suspension, which was stored at −80°C. Production
media (chemically defined media 4 [49] for rapamycin, liquid ISP2
media for FK520) were inoculated with spore suspension and
grown with shaking at 25°C for 5–7 days. The method for purifica-
tion of FK520 and rapamycin was adapted from Kino et al. [50]. The
mycelium was collected after centrifugation, and either FK520 or
rapamycin was extracted with methanol. This crude mixture was
concentrated, and organic compounds were extracted with ethyl
acetate and washed with brine. This crude extract was further puri-
fied via silica column chromatography, using a gradient of 1:1 to
3:1 ethylacetate:hexane.
YTH Reagents
We have constructed a unique set of YTH reagents to assay the
activity of various peptides in the LiRP system. We generated a
derivative of YTH strain PJ69-4A [51] for use in experiments that
include both rapamycin and FKBPs. Rapamycin binds endogenous
FKBPs in yeast, leading to inhibition of the TOR1 and TOR2 pro-
teins, followed by G1 phase cell cycle arrest [38]. We have intro-
duced tor2-1 and Dfpr1 alleles into the genome of PJ69-4A to nul-
lify the effects of rapamycin [38, 52]. Deletion of FPR1, the major
FKBP in yeast, reduces intracellular competition for binding to ra-
pamycin, thus facilitating its participation in the YTH interaction.
The TOR2 mutation renders the yeast target of rapamycin insensi-
tive to the growth-arresting effects of rapamycin, precluding the
possibility of complementing the Dfpr1 allele when expressing
FKBP fusion proteins [53].
Strain Generation
S. cerevisiae strain PJ69-4A (MATa trp1-901 leu2-3,112 ura3-52
his3-200 gal4D gal80D GAL2-ADE2 LYS2::GAL1-HIS3 met2::GAL7-
lacZ) genomic DNA was used as PCR template with primers 1/2
and 3/4 (for a list of primers, see the Supplemental Data available
with this article online). PCR products were digested with Xba1 and
ligated. The ligation product was used as template for a second
round of PCR using primers 1/3. The resulting 519 bp product en-
codes a portion of TOR2 from S. cerevisiae (GenBank accession
number NC_001143, locus tag YKL203C) with S1975R point muta-
tion. In addition, a silent mutation generating an Xba1 site was in-
troduced at nucleotide 5913. Gel-purified 519 bp fragment was
transformed into S. cerevisiae strain PJ69-4A and plated onto YPD +
100 ng/ml rapamycin. Rapamycin-resistant colonies were streakedonto YPD + 100ng/ml rapamycin plates for individual colonies. Indi-
vidual colonies were grown in YPD followed by isolation of genomic
DNA. PJ69-4A (tor2-1) strains were identified by PCR amplifying
from genomic DNA using primers 5/6 and digesting the product
with Xba1. PCR with primers 7/8 and plasmid pFA6a-kanMX4 gen-
erated the kanMX4 disruption cassette [54] flanked on both 5# and
3# termini with 45 bp of sequence surrounding the S. cerevisiae
FPR1 ORF (GenBank accession number NC_001146, locus tag
YNL135C). This fragment was transformed into PJ69-4A (tor2-1)
followed by plating onto YPD + 200 mg/l G418. G418 resistant colo-
nies were streaked onto YPD + 200 mg/l G418 plates for individual
colonies. Individual colonies were grown in YPD followed by isola-
tion of genomic DNA. PJ69-4A (tor2-1 Dfpr1) strains were identified
by PCR amplifying from genomic DNA using primers 9/10/11 and
screening for a 915 bp product. PJ69-4A (tor2-1 Dfpr1) strains were
confirmed by sequencing PCR products from genomic DNA. PCR
with primers 9/11 generated a product that was gel purified and
sequenced with primer 12. PCR with primers 13/14 generated a
product that was gel purified and sequenced with primer 15. PCR
with primers 5/6 generated a product that was gel purified and
sequenced with primer 16. The integrity of the recombination junc-
tions and the presence of the tor2-1 allele were confirmed by ana-
lyzing sequence data.
Plasmids
hFKBP12 (GenBank accession number NM_000801; residues
2–108), hFRB (GenBank accession number NM_004958; residues
2023–2112), and hRb A + B domains (GenBank accession number
M28419; residues 380–785) were amplified using a human B cell
cDNA library as template. PCR with primers 17/18 generated a
product that was cloned into the Nde1/EcoR1 sites of plasmid
pGBKT7 (Clontech) to give plasmid pBait-12. PCR with primers 19/
20 generated a product that was cloned into the Spe1/EcoR1 sites
of plasmid pGADGH (Clontech) to give plasmid pPrey-FRB. PCR
with primers 21/22 generated a product that was cloned into the
EcoR1/BamH1 sites of pGBKT7 to give pBait-hRb. PCR with prim-
ers 23/24 and 25/20 generated products that were used in SOE
PCR and cloned into the Spe1/EcoR1 sites of plasmid pGADGH to
give plasmid pPrey-12-FRB-2023. PCR with primers 26/20 using
plasmid pPrey-12-FRB-2023 as template generated a product that
was cloned into the BamH1/EcoR1 sites of plasmid pPrey-12-FRB-
2023 to give plasmid pPrey-12-FRB-2021. Quickchange mutagene-
sis with primers 27/28 on plasmid pPrey-12-FRB-2021 generated
plasmid pPrey-12-FRB. PCR with primers 29/30 and 31/32 using
plasmid pPrey-12-FRB or plasmid pGEX2TK (Pharmacia), respec-
tively, as template generated products cloned into the Spe1/Xho1
sites of plasmid pGADGH to give plasmid pPrey-Scaffold. Plasmid
pPrey-Scaffold encodes an AD-HA epitope tag-hFKBP12 (amino
acids 2–108)-ELSSGS-hFRB (amino acids 2021–2112, T2098L)-EF-
GST (amino acids 2–218 of S. japonicum GST) fusion protein. Prim-
ers 33/34, 35/36, or 37/38 were annealed and extended using
Klenow DNA polymerase. Products were cloned into Sac1/BamH1
sites of plasmid pPrey-Scaffold to give plasmids pPrey-12-LYCYE-
FRB-GST, pPrey-12-DLYCYEQ-FRB-GST, and pPrey-12-DLYCY-
EQLN-FRB-GST, respectively. PCR with primers 33 and 20 using
plasmid pPrey-12-LYCYE-FRB-GST as template generated a prod-
uct that was cloned into the SacI/EcoRI sites of plasmid pPrey-12-
FRB to give plasmid pPrey-12-LYCYE-FRB. PCR with primers 39/
23 generated a product that was cloned into the Spe1/EcoR1 sites
of plasmid pGADGH to give plasmid pPrey-12. Mouse c-Src (Gen-
Bank accession number BC039953, amino acids 1–250) was ampli-
fied from the plasmid pmc-Src-CMV using primers 40/41, and the
resulting PCR fragment was digested with EcoR1/Sal1. This insert
was ligated into EcoR1/Sal1-cut pGBKT7 to generate the plasmid
pDB-SrcN. Mouse p130Cas (GenBank accession number U28151)
was PCR amplified using primers 42/43, and the resulting PCR
fragment was digested with BamH1/EcoR1. The insert was ligated
to BamH1/EcoR1-cut pGAD-GH to produce plasmid pAD-Cas.
Primers 44/45 and 46/47 were annealed and extended using
Klenow DNA polymerase. Products were digested with Sac1/
BamH1 and cloned into plasmid pPrey-12-FRB to generate plas-
mids pPrey-12-RALPPLP-FRB and pPrey-12-PPLPPR-FRB. Spe1/
BamH1 fragments from these two plasmids were cloned into plas-
mid pPrey-Scaffold to generate plasmids pPrey-12-RALPPLP-
FRB-GST and pPrey-12-PPLPPR-FRB-GST. PCR with primers 48/
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85449 generated a product that was cloned into the NcoI/SmaI sites o
mof plasmid pGBKT7 to generate plasmid pBait-α1 (mouse AMPK-
α1; GenBank accession number AY885266). 3
a
TYTH Experiments
oBait plasmids contain the TRP1 selection marker. Prey plasmids
Lcontain the LEU2 selection marker. Bait and prey plasmids were
ltransformed into strain PJ69-4A (tor2-1 Dfpr1) and plated onto SC-
fLeu-Trp media. Plasmid-containing strains were patched onto SC-
tLeu-Trp followed by replica plating onto SC-Leu-Trp-Adenine ± 1
M rapamycin or SC-Leu-Trp-Adenine ± 1 M FK520. Replica
plates were allowed to incubate 2–3 days prior to image acquisi-
Stion. Liquid culture assays were performed to determine the dose
Tresponse of YTH interactions. Test strains were grown overnight in
wSC-Leu-Trp media in the presence of 1 M rapamycin to prevent
fexpression of reporter genes. Separate flasks with SC-Leu-Trp-Ad-
enine ± rapamycin or rapamycin analog AP23102 (Ariad Pharma-
ceuticals) at varying concentrations were inoculated to OD600 A
w0.05. Growth was monitored by determining OD600 at multiple
time points until saturation of the culture. W
B
bWestern Blots
tStrains containing bait and prey plasmids were grown overnight in
oSC-Leu-Trp to OD600 w0.8–1.1. An equivalent number of cells were
gpelleted for each culture (4 OD600 units). Cell pellets were resus-
tpended in 100 l sample buffer (100 mM Tris-HCl pH = 6.8, 4%
fw/v SDS, 2% v/v β-mercaptoethanol, 0.001% w/v bromophenol
blue, 20% glycerol) and w50 l of 0.5 mm glass beads. Cell sus-
pension was vortexed for 1 min followed by incubating for 5 min at R
100°C. Ten microliter sample/lane was resolved using 12% SDS- R
PAGE. Gels were blotted onto 0.45 m nitrocellulose membrane or A
stained using Coomassie Brilliant Blue R-250. Nitrocellulose mem- P
brane was probed with mouse anti-HA monoclonal antibody
(Sigma) followed by goat anti-mouse alkaline phosphatase conju- Rgate (Sigma). Alkaline phosphatase activity was resolved using
chemiluminescent detection (Pierce).
Plasmid DNA Library Synthesis
Plasmid DNA library synthesis followed published protocols [55].
Briefly, duplex DNA library insert was synthesized by annealing oli-
gonucleotides 5#-GTG CAT CGG GTT GAG CTC (NNS)7 GGA TCC
ACT GTA GGT CAC-3# (N = 25% A, 25% G, 25% C, 25% T; S =
50% G, 50% C) and 5#-GTG ACC TAC AGT GGA TCC-3# (IDT) fol-
lowed by primer extension using Klenow DNA polymerase in the
presence of dNTPs. Duplex DNA library insert was digested with
SacI/BamHI and gel purified. Plasmid vector pPrey-Scaffold was
digested with SacI/BamHI, CIAP treated, and gel purified. DNA li-
brary insert and vector were ligated using T4 DNA ligase and de-
salted using gel filtration (Centri-Sep, Princeton separations). Plas-
mid DNA library was transformed into E. coli strain MC1061 using
ten independent electroporations (20 kV/cm; 200 ; 25 F). After
recovery in SOC media for 1 hr at 37°C, independent electropor-
ations were pooled in 1 liter LB + AMP (50 g/ml). Aliquots of the
pooled electroporations were serially diluted followed by plating
onto LB + AMP (50 g/ml) to titer the overall number of trans-
formants. Pooled electroporations were grown overnight in 1 liter
LB + AMP (50 g/ml) followed by large-scale plasmid purification
(Promega wizard megaprep kit). Overall, w7.5 × 107 independent
transformants were amplified to give w1.5 mg of plasmid DNA li-
brary. Seventeen independent transformants were chosen at ran- 1
dom for DNA sequencing. Library members contained the desired
insert (w52%), inserts greater than unit length (w11%; resulting
from ligation of multiple library inserts), no insert (w17%), or clones 1
missing portions of FKBP, FRB, and/or GST (w17%) likely resulting
from restriction enzyme star activity.
1Combinatorial Peptide Library Selection Experiments
Large-scale transformations of YTH strain PJ69-4A (tor2-1 Dfpr1)
followed published protocols [56]. Briefly, 20–60 g of plasmid DNA
library was transformed into YTH strain PJ69-4A (tor2-1 Dfpr1) con-
1taining various bait plasmids. Serially diluted aliquots of the initial
transformation were plated onto SC-Leu-Trp plates to determine
the overall number of yeast transformants. The remaining amountf the initial transformation was plated onto SC-Leu-Trp-His + 3
M 3-amino-1,2,4-triazole (3-AT; Sigma) plates and incubated at
0°C for 1 week. Colonies showing a His+ phenotype were counted,
nd either all or a subset of colonies were patched onto SC-Leu-
rp plates. Patches from SC-Leu-Trp plates were replica plated
nto SC-Leu-Trp-Adenine ± 1 M rapamycin or SC-Leu-Trp plates.
ibrary plasmids were rescued from His+ colonies following pub-
ished protocols [57]. Rescued library plasmids were sequenced
ollowed by retransformation into YTH strain PJ69-4A (tor2-1 Dfpr1)
o confirm plasmid linkage of phenotypes.
upplemental Data
he Supplemental Data include a list of primers and can be found
ith this article online at http://www.chembiol.com/cgi/content/
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